Surgery, Gastroenterology and Oncology
Vol. 24, No. 4, Aug 2019
Large Cell Neuroendocrine Carcinoma (LCNEC) of the Colon Arising from a Tubulovillous Adenoma: A Case Report and Literature Review
Jonathan L Dameworth, Luc Colburn, Daniel Mistrot, M Frances Hahn, Raymond Shamos, David Row
Images in Clinical Medicine, Aug 2019
Article DOI: 10.21614/sgo-24-4-210
A 66-year-old man was found to have a 4 cm mass in the distal transverse colon that was biopsied on a diagnostic colonoscopy performed for occult anemia. Pathology showed incomplete removal of a tubulovillous adenoma with high-grade dysplasia. The patient underwent surgical resection, with final pathology demonstrating two 5 mm foci of large cell neuroendocrine carcinoma (LCNEC) within a background of tubulovillous adenoma, and 1 of 8 positive lymph nodes.
Poorly-differentiated neuroendocrine tumors (NET) are termed neuroendocrine carcinoma (NEC), and are extremely rare. Colorectal LCNEC have been identified in synchronicity or association with adenomas and adenocarcinomas (AC).
There are several theories that attempt to explain the pathogenesis of colorectal tumors with concurrent neuroendocrine and adenomatous pathology:
(1) mixed tumors are a neuroendocrine phenotype of dedifferentiated adenocarcinoma;
(2) these tumors originate from a common multipotent stem cell then simultaneously differentiate into glandular or neuroendocrine lineages; or,
(3) a common genetic alteration predisposes an individual to the development of both tumor types.

More work is needed to delineate the true pathogenesis of colorectal tumors with concurrent neuroendocrine and adenomatous pathology. There are no agreed-upon management guidelines for colorectal NEC, although given its highly aggressive nature, standard oncologic resection and adjuvant platinum-based chemotherapy are generally recommended for patients with resectable disease.

Full Text Sources: Download pdf
Abstract:   Abstract EN
Views: 3665


Watch Video Articles


For Authors



Journal Subscriptions

Current Issue

Dec 2025

Supplements

Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)

e-ISSN: 2601 - 1700 (online)

ISSN-L: 2559 - 723X

Journal Abbreviation: Surg. Gastroenterol. Oncol.

Surgery, Gastroenterology and Oncology (SGO) is indexed in:
  • SCOPUS
  • EBSCO
  • DOI/Crossref
  • Google Scholar
  • SCImago
  • Harvard Library
  • Open Academic Journals Index (OAJI)

Open Access Statement

Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.

Journal Metrics

Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2



Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019

Creative Commons License
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.